

Chris Wallace



Jenn Asimit



Mary Fortune




Dan Rainbow








#### Manhattan plots (haystack plots?)



How do we use GWAS to identify disease genes/proteins and drug targets?

#### Manhattan plots (haystack plots?)



How do we use GWAS to identify disease genes/proteins and drug targets?

#### Overview

• Fine mapping causal variants


• Joint tagging of causal variants


Improved fine mapping by exploiting shared aetiology


• Functional validation of causal effects on IL2RA


Fine mapping causal variants


## Association of MS and T1D in IL2RA region















# Stepwise search of IL2RA region


#### MS


SNP	р
rs2104286	$< 2 \times 10^{-16}$
rs11256593	$1 \times 10^{-5}$


#### T1D


SNP	р
rs61839660	$< 2 \times 10^{-16}$
rs11594656	$7 \times 10^{-12}$
rs12220852	$1 \times 10^{-9}$
rs41295159	$1 \times 10^{-7}$
























### Stochastic search of IL2RA region



# (Dis-) agreement between stepwise and stochastic search

#### <u>MS</u>

Stepwise Stochastic	rs2104286 (B)	rs11256593
M1: rs2104286 (B)	1.00	0.33
M2: rs12722496 (A) M2: rs56382813 (D)	0.33 0.31	0.08 0.29

 $r^2$  between SNPs

#### T<sub>1</sub>D

Stepwise Stochastic	rs61839660 (A)	rs11594656 (C)	rs12220852 (E)	rs41295159 (F)
rs12722496 (A)	0.88	0.02	0.02	0.00
rs11594656 (C)	0.02	1.00	0.26	0.02
rs6602437 (E)	0.05	0.25	0.62	0.01
rs41295159 (F)	0.00	0.02	0.00	1.00

## Systematic comparison: 89 genetic regions, 6 diseases

Group	Number	Group	Number
Autoimm. Thyroid Disease, ATD	2772	Celiac Disease, CEL	12041
Juvenile Idiopathic Arthritis, JIA	1214	Multiple Sclerosis, MS	4461
Rhemuatoid Arthritis, RA	11475	Type 1 Diabetes, T1D	6681
CONTROL	22997		

201 region/disease pairs showing association (min.  $p < 10^{-6}$ )

### Systematic comparison: 89 genetic regions, 6 diseases

Group	Number	Group	Number
Autoimm. Thyroid Disease, ATD	2772	Celiac Disease, CEL	12041
Juvenile Idiopathic Arthritis, JIA	1214	Multiple Sclerosis, MS	4461
Rhemuatoid Arthritis, RA	11475	Type 1 Diabetes, T1D	6681
CONTROL	22997		

#### 201 region/disease pairs showing association (min. $p < 10^{-6}$ )

Regions	Region-disease pairs	
62	171	matched
2	2	stochastic null ( $p \simeq 1 \times 10^{-6}$ )
15	17	stepwise nested in stochastic
5	5	different top SNP (two weak signals)
5	6	non-nested mismatch

# Systematic comparison: 89 genetic regions, 6 diseases

Group	Number	Group	Number
Autoimm. Thyroid Disease, ATD	2772	Celiac Disease, CEL	12041
Juvenile Idiopathic Arthritis, JIA	1214	Multiple Sclerosis, MS	4461
Rhemuatoid Arthritis, RA	11475	Type 1 Diabetes, T1D	6681
CONTROL	22997		


#### 201 region/disease pairs showing association (min. $p < 10^{-6}$ )

Regions	Region-disease pairs	
62	171	matched
2	2	stochastic null ( $p \simeq 1 \times 10^{-6}$ )
15	17	stepwise nested in stochastic
5	5	different top SNP (two weak signals)
5	6	non-nested mismatch


20/30 regions with > 1 associated disease had a shared signal

Joint tagging of causal variants


## Haplotype analysis of MS




## Stochastic search "correctness" sample size dependent



#### Stochastic search "correctness" sample size dependent



#### Stochastic search "correctness" sample size dependent



### Conditions for joint tagging


SNPs  $X_i$ , i = 1, ..., p.  $X_1, ..., X_k$  are causal (k < p) correlation matrix is  $\Sigma$ 

Expected Z score from a joint model is  $\mu$ 


$$\mu_i = \begin{cases} f(MAF, OR, N) & i \le k \\ 0 & i > k \end{cases}$$

Marginal Z scores across all SNPs:

$$Z \sim N(\Sigma \mu, \Sigma)$$




#### A, D causal, similar effects: expect B to have smallest p value




### Effect of $\Sigma$ on potential for joint tagging

SNPs 1, 2 causal. SNP 3 potential tag.  $\mu=({\rm 1,1,0})'$ 




### Effect of $\Sigma$ on potential for joint tagging

SNPs 1, 2 causal. SNP 3 potential tag.  $\mu=(1,1,0)'$ 




### Effect of $\Sigma$ on potential for joint tagging

SNPs 1, 2 causal. SNP 3 potential tag.  $\mu = (1, 1, 0)'$ 




# Effect of $\Sigma$ on potential for joint tagging

SNPs 1, 2 causal. SNP 3 potential tag.  $\mu=(1,1,0)'$ 




# Effect of $\Sigma$ on potential for joint tagging

SNPs 1, 2 causal. SNP 3 potential tag.  $\mu = (1,1,0)'$ 



# Potential tags by LD pattern at 20% of variant pairs



# Improved fine mapping by exploiting shared aetiology

# Bayesian fine mapping


#### Single disease

Model	Prior	Data	Posterior
А	$\pi_{\mathcal{A}}$	$BF_A$	$\propto \pi_A B F_A$
В	$\pi_B$	$BF_B$	$\propto \pi_B B F_B$
D	$\pi_{D}$	$BF_D$	$\propto \pi_{D} B F_{D}$
B+D	$\pi_{B+D}$	$BF_{B+D}$	$\propto \pi_{B+D}BF_{B+D}$
:	÷	÷	:

# Bayesian fine mapping

#### Two diseases

Disease 1				
Model	Data			
Α	$BF_A$			
В	$BF_B$			
D	$BF_D$			
B+D	$BF_{B+D}$			
:	÷			




Disease 2				
Model	Data			
А	$BF_A$			
В	$BF_B$			
D	$BF_D$			
B+D	$BF_{B+D}$			
:	:			

# Bayesian fine mapping

#### Two diseases

Disease 1				
Model	Data			
А	$BF_A$			
В	$BF_B$			
D	$BF_D$			
B+D	$BF_{B+D}$			
:				



Disease 2			
Model	Data		
А	$BF_A$		
В	$BF_B$		
D	$BF_D$		
B+D	$BF_{B+D}$		
:	:		

#### Use prior to borrow information between diseases

Define configurations: sets of models for each disease

$$C_{i,j} = \{M_i \text{ for disease 1}, M_j \text{ for disease 2}\}$$

$$Pr(C_{i,j}) = \begin{cases} Pr(M_i)Pr(M_j) \times \kappa \times \tau_{ij} & M_i \cap M_j \neq \emptyset \\ Pr(M_i)Pr(M_j) \times 1 \times \tau_{ij} & M_i \cap M_j = \emptyset \end{cases}$$

$$\begin{array}{c} A+D \\ \hline \end{array} \begin{array}{c} \kappa = 1 \\ \hline \end{array} \begin{array}{c} B \\ \hline \end{array} \begin{array}{c} \kappa > 1 \\ \hline \end{array} \begin{array}{c} A+C \\ \hline \end{array}$$

 $\kappa$ : upweighting factor

 $au_{ij}$ : normalisation factor, fixes prior on the number of causal variants

# Computational challenges of Bayesian fine mapping

#### Single disease

Model	Prior	Data	Posterior	
А	$\pi_{\mathcal{A}}$	$BF_A$	$\propto \pi_A B F_A$	
В	$\pi_{B}$	$BF_B$	$\propto \pi_B B F_B$	
D	$\pi_{D}$	$BF_D$	$\propto \pi_{D} BF_{D}$	
B+D	$\pi_{B+D}$	$BF_{B+D}$	$\propto \pi_{B+D}BF_{B+D}$	
:	:	:	:	

Model space: exponential in number of causal variants

# Computational challenges of Bayesian fine mapping

#### Two diseases

Disease 1		•	Disease 2	
Model	Data		Model	Data
А	$BF_A$		А	$BF_A$
В	$BF_B$		В	$BF_B$
D	$BF_D$		D	$BF_D$
B+D	$BF_{B+D}$		B+D	$BF_{B+D}$
÷	÷		:	:

Model space: (exp. causal variants)<sup>number of diseases</sup>

Challenges: memory, computational time

#### Fast, memory efficient calculation of marginal posteriors

Speed: Joint Bayes factor approximated by function of single disease Bayes factors

$$BF(\{M_i,M_j\}) \lesssim BF(M_i) \times BF(M_j) \times \eta$$

 $\eta$  function of numbers of cases, shared controls and causal variants

Memory: linear (not exponential) in number of diseases, by storing only marginal single disease posteriors

#### Fast, memory efficient calculation of marginal posteriors

Speed: Joint Bayes factor approximated by function of single disease Bayes factors

$$BF(\{M_i, M_j\}) \lesssim BF(M_i) \times BF(M_j) \times \eta$$


 $\eta$  function of numbers of cases, shared controls and causal variants

Memory: linear (not exponential) in number of diseases, by storing only marginal single disease posteriors


● Running time: 15 seconds (2 diseases) — 83 seconds (6 diseases)

5 https://github.com/jennasimit/MTFM

# Joint fine mapping improves accuracy at smaller sample sizes



# Joint fine mapping improves accuracy at smaller sample sizes



# Joint fine mapping of 30 regions

7/30 regions differed between single and multi-disease analysis 4/4 cases: MFM results matched single disease analysis in larger international dataset

Region	Disease	Stochastic	MFM	Mean $r^2$
1p	RA	D/rs4648662	C/rs10752749	0.36
	iRA	C/rs141426426	C/rs10797431	
6q	RA	G/rs56258221	C/rs72928038	0.33
BACH2	iRA	C/rs72928038	C/rs72928038	
18p	CEL	F/rs34799913	C/rs12967678	0.4
PTPN2	iCEL	C/rs67878610	C/rs12967678	
10p	MS	B/rs2104286	A/rs12722496 + D/rs7089861	0.2, 0.3
IL2RA	iMS	A/rs12722496 + D/rs56382813	A/rs12722496 + D/rs7089861	

# \_\_\_\_


Functional validation of causal

effects on IL2RA


#### Allele specific expression


**Allele specific expression**: quantify relative expression of two chromosomes using targetted PCR and sequencing


Within-individual: controls for between individual variation in environment, other genetics etc


























#### Summary

- Finding associated variants by GWAS variants is "easy"
- Fine mapping is harder
- Knowing causal variants, mechanism can be explored, or explicitly tested (ASE, Hi-C, eQTL, chipseq, CRISPR)

#### Joint tagging is a thing

- Most regions likely to contain > 1 causal variants
- ullet Joint tagging might affect  $\sim 20\%$  of causal variant pairs
- Key assumptions in stepwise search are not about number of / LD between causal variants, but about whether another SNP exists which acts as a lower dimensional summary of disease effect

#### Reasons for caution

- IL2RA "famous": multiple, complex associations
- Other regions of greatest a-priori interest show strongest associations, learning they are also complex (e.g. *IL2*, *CTLA4*)

What if all regions are "complex"?

#### Reasons for optimism

- Borrowing information between related diseases can help overcome sample size limitations
- Inference on shared/distinct genetic causality comes "for free"



#### Thanks to



Jenn Asimit



Mary Fortune



Dan Rainbow

Linda Wicker

Disease investigators Steve Eyre (RA), Steve Rich, John Todd (T1D), Stephen Sawcer, IMSGC (MS), Wendy Thomson (JIA), David van Heel (celiac disease), Stephen Gough (ATD)


Cambridge NIHR BioResource









#### Individuals with rare recombination events



#### Individuals with rare recombination events



#### T cell subsets in immune-mediated diseases



#### T cell subsets in immune-mediated diseases

